Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct:60:102999.
doi: 10.1016/j.ebiom.2020.102999. Epub 2020 Sep 16.

Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study

Mar Masiá  1 , Marta Fernández-González  2 , Sergio Padilla  2 , Piedad Ortega  2 , José A García  3 , Vanesa Agulló  2 , Javier García-Abellán  2 , Guillermo Telenti  2 , Lucía Guillén  2 , Félix Gutiérrez  4
Affiliations

Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study

Mar Masiá et al. EBioMedicine. 2020 Oct.

Abstract

Background: The virological and immunological effects of the immunomodulatory drugs used for COVID-19 remain unknown. We evaluated the impact of interleukin (IL)-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and the antibody response in patients with COVID-19.

Methods: Prospective cohort study in patients admitted with COVID-19. Serial nasopharyngeal and plasma samples were measured for SARS-CoV-2 RNA and S-IgG/N-IgG titers, respectively.

Findings: 138 patients with confirmed infection were included; 76 (55%) underwent IL-6 blockade. Median initial SOFA (p = 0•016) and SARS-CoV-2 viral load (p<0•001, Mann-Whitney-Wilcoxon test) were significantly higher among anti-IL-6 users. Patients under IL-6 blockade showed delayed viral clearance in the Kaplan-Meier curves (HR 0•35 [95%CI] [0•15-0•81], log-rank p = 0•014), but an adjusted propensity score matching model did not demonstrate a significant relationship of IL-6 blockade with viral clearance (HR 1•63 [0•35-7•7]). Cox regression showed an inverse association between SARS-CoV-2 RNA clearance and the initial viral load (HR 0•35 [0•11-0•89]). Patients under the IL-6 blocker showed shorter median time to seropositivity, higher peak antibody titers, and higher cumulative proportion of seropositivity in the Kaplan Meier curves (HR 3•1 [1•9-5] for S-IgG; and HR 3•0 [1•9-4•9] for N-IgG; log-rank p<0•001 for both). However, no significant differences between groups were found in either S-IgG (HR 1•56 [0•41-6•0]) nor N-IgG (HR 0•96 [0•26-3•5]) responses in an adjusted propensity score analysis.

Interpretation: Our results suggest that in patients infected with SARS-CoV-2, IL-6 blockade does not impair the viral specific antibody responses. Although a delayed viral clearance was observed, it was driven by a higher initial viral load. The study supports the safety of this therapy in patients with COVID-19.

Funding: Instituto de salud Carlos III (Spain).

Keywords: Anti-cytokine therapy; Antibody responses; COVID-19; N-IgG; S-IgG; SARS-CoV-2; Tocilizumab; Viral kinetics.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interests Dr. Gutiérrez reports personal fees from Janssen-Cilag and from ViiV Health Care, outside the submitted work. The other authors have nothing to disclose.

Figures

Fig. 1
Fig. 1
Kaplan Meier curve to estimate the cumulative proportion of patients with detectable viral RNA according to therapy with tocilizumab. (a) Unadjusted. (b) Adjusted (Wald test).
Fig. 2
Fig. 2
Median time from the onset of symptoms to seropositivity according to therapy with tocilizumab (Mann-Whitney-Wilcoxon test). (a) S-IgG. (b) N-IgG.
Fig. 3
Fig. 3
IgG titers according to therapy with tocilizumab (Mann-Whitney-Wilcoxon test). (a) Peak S-IgG. (b) Peak N-IgG. (c) Peak S-IgG after excluding non seroconverters. (d) Peak N-IgG after excluding non seroconverters.
Fig. 4
Fig. 4
Kaplan Meier curve to estimate the cumulative proportion of patients with negative titers of IgG according to therapy with tocilizumab. (a) S-IgG (unadjusted). (b) N-IgG (unadjusted). (c) S-IgG (adjusted) (log-rank test). (d) N-IgG (adjusted) (log-rank test).
See this image and copyright information in PMC

Comment in

References

    1. Zhou Y., Fu B., Zheng X. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl Sci Rev. 2020 [in press] - PMC - PubMed
    1. Mihara M., Kasutani K., Okazaki M. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5:1731–1740. - PubMed
    1. Fu B., Xu X., Wei H. Why tocilizumab could be an effective treatment for severe COVID-19. J Transl Med. 2020;18:164. - PMC - PubMed
    1. Xu X., Han M., Li T. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117:10970–10975. - PMC - PubMed
    1. Toniati P., Piva S., Cattalini M. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19 - PMC - PubMed

MeSH terms